A $2.4 billion deal
According to Cencora, the deal is structured flexibly to extend its control while keeping shareholders committed to AON on board. Key points:
- Cencora will pay $2.3 billion at closing, plus contingent value rights worth up to $100 million tied to certain conditions.
- Certain AON shareholders may retain up to a 25% equity stake through a rollover arrangement.
- In that case, Cencora expects to pay about $1.7 billion to raise its ownership to 75%.
- The acquisition is expected to boost adjusted earnings per share from the second year after closing.
A new piece in the community oncology strategy
In 2025, Cencora took majority control of OneOncology in a $5 billion deal. Analysts say AON adds a distinct segment: while OneOncology focuses on larger community oncology providers, AON targets smaller ones.

















